KBI's Leadership Team Discusses Operational Consolidation with Selexis at BIO International 2023
The recent operational consolidation of KBI Biopharma, Inc. and Selexis SA brings a streamlined approach to support customers in rapidly accelerating...
News (2)
KBI Biopharma Unveils KBI PUREplatform™, a Game-Changing Microbial Expression Offering to Redefine Biopharmaceutical Manufacturing
Platform leverages proprietary PUREcoli™ strain and cutting-edge screening packages for unmatched efficiencies and optimized production processes...
JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organization, Providing Seamless Experience for Partners
KBI’s new model will enhance operational efficiencies, drive strategic clarity, and accelerate innovation for global biopharma customers Sunnyvale,...
KBI Biopharma Appoints Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific Officer
Durham, North Carolina (May 10, 2023) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the appointment of Marykay...
KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After Opening
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully. GENEVA, March 21, 2023 – KBI Biopharma, Inc. (KBI),...
KBI Biopharma Announced as 2023 ISPE Facility of the Year Submission Finalist
KBI Biopharma is thrilled to announce that Patriot Park has been named a finalist in the 2023 ISPE Facility of the Year Awards (FOYA) in two...
KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment
Following the recent Sudan ebolavirus outbreak in Uganda, KBI is providing emergency support through global production efforts. DURHAM, NC (January...
KBI Biopharma, Inc. Secures Swissmedic Regulatory Establishment License for State-of-the-Art Mammalian Cell Manufacturing Facility in Geneva
Major regulatory milestone demonstrates compliance with stringent standards for cGMP drug substance manufacturing. GENEVA, December 20, 2022– KBI...
A Look Back at 2022
What a year 2022 turned out to be! It was a year of growth and expansion, from the launch of our new KBI commercial manufacturing facility in...
Leuven Lives up to KBI's High Quality Expectations
The KBI Biopharma analytical facility in Leuven, Belgium, has received a successful inspection from Belgium’s regulatory authority, the Federal...